Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Antibody-drug conjugates: Principles and opportunities

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

An overview of the principles and prospects of ADC drugs

Antibody-drug conjugates—an emerging class of cancer treatment

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities

Antibody drug conjugates in the clinic

Advances and Limitations of Antibody Drug Conjugates for Cancer

Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement

Strategies and challenges for the next generation of antibody–drug conjugates

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

[Basics and Innovations in Antibody-Drug Conjugates]

Antibody-drug Conjugates: Design and Clinical Progress

Antibody-Drug Conjugates: A promising breakthrough in cancer therapy

Targeting cancer with antibody-drug conjugates: Promises and challenges

Potential of antibody–drug conjugates (ADCs) for cancer therapy

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Exploring the next generation of antibody–drug conjugates

Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy